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Abstract  
There is a long history of using both in silico and in vitro methods to predict adverse effects in humans 
and environmental species where toxicity data are lacking. Currently there is a great deal of interest in 
applying these methods to the development of so-called adverse outcome pathway (AOP) constructs. 
The AOP approach provides a framework for organising information at the chemical and biological 
level, allowing evidence from both in silico and in vitro studies to be rationally combined to fill gaps in 
knowledge concerning toxicological events. Fundamental to this new paradigm is a greater 
understanding of the mechanisms of toxicity and in particular where these mechanisms may be 
conserved across taxa, such as between model animals and related wild species. This presents an 
opportunity to make predictions across diverse species, where empirical data are unlikely to become 
available as is the case for most species of wildlife. 
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Introduction 
The adverse effects of man-made chemicals (such as pesticides, industrial chemicals and 
intermediates) on the environment have long been established as a cause for concern in 
ecotoxicology. The potential effects of pharmaceuticals on wildlife species has been highlighted as an 
issue of particular concern since their initial detection in the environment. Whilst toxicity data are 
obtainable for certain species and endpoints, the effects of pharmaceuticals on the full diversity of 
wildlife cannot be readily determined, therefore predictive toxicological methods are essential. There is 
now greater understanding of the fundamental interactions between chemicals and biological systems 
enabling more rational, mechanistically-based predictions of toxicity to be proposed. In developing 
these mechanistically-based models, knowledge of in vivo outcomes is considered most useful. 
However, this information is usually unavailable, particularly for repeat, low dose exposure, 
characteristic of pharmaceuticals in the environment. Hence, knowledge acquired through the 
application of in silico and in vitro tools becomes invaluable. 
The concept of toxicity pathways, whereby an initial perturbation of a biological system leads to a 
subsequent adverse effect in an organism, has been an important theory within toxicology for many 
years. In the last decade there has been an increased interest in this philosophy and recent 
developments have seen the concept evolve into the adverse outcome pathway (AOP) approach. This 
approach enables information from diverse sources to be organised within a logical framework 
facilitating greater understanding of the processes involved. Deconstruction of these pathways into a 
sequence of finite key events provides an opportunity to use mechanistic information obtained from in 
vitro and in silico analysis to fill gaps in current knowledge. Where key events within pathways are 
conserved across species, models that are applicable across a diverse range of organisms may be 
developed. In the present paper, we discuss the AOP framework and its application to the problem of 
predicting toxic effects in wildlife species as well as describing advances in both in silico and in vitro 
sciences which may help to resolve this complex issue. 
 
Adverse outcome pathways in (eco)toxicology 
Definition, structure and development of adverse outcome pathways 
Mechanistic toxicology is a cornerstone of ecological and human risk assessment. AOPs play a major 
role in this paradigm providing a framework to organise events from the initial interaction of a chemical 
with a biological target, termed the molecular initiating event (MIE; for example ligand-receptor 
interactions or binding of the chemical to proteins or nucleic acids), and an adverse outcome at the 
organism or population level [1, 2]. Previous constructs, such as the source to outcome pathway 
(which includes consideration of the source of pollution and effects up to the level of community or 
ecosystem), and mechanism or mode-of-action pathways are well established in the area of 
environmental risk assessment. Uncertainty caused by differences in use and definition of the terms 
mode-of-action and mechanism-of-action have been overcome by the introduction of the AOP 
construct which requires both the MIE and the adverse outcome to be defining anchor points. Whilst 
AOPs are not conceptually new, they represent an evolution of previous constructs and are designed 
to be more appropriate to risk assessment [1]. An AOP consists of three blocks of information, namely 
(i) the MIE (ii) a set of key events and (iii) the adverse outcome [2]. For a given AOP, the MIE and the 
adverse outcome are the two defining anchor points. These are important as one MIE may result in a 
range of adverse outcomes, and similarly, a given adverse outcome may be a consequence of 
different MIEs. An AOP may involve as many key events as necessary; these are essential for 
generating the adverse outcome [2, 3]. An advantage of the AOP approach is its ability to incorporate 
data from a wide range of sources (in silico, in vitro, in vivo etc) and use this information to provide the 
linkages between the MIE and the adverse outcome [1]. Whilst mechanistic information is not 
essential a priori to develop an AOP, as this information becomes available it can be used as further 
supporting evidence. Greater understanding of the mechanisms driving the processes within the 
pathway can be used to provide justification in extrapolating from known to unknown conditions. One 
drawback of the AOP approach is the lack of explicit consideration of external and internal exposure 
which ultimately determines the concentration of a chemical at the target site. However, using the 
organisational framework of an AOP it is possible to determine what dosimetry information would be 
necessary to allow dose in an assay, or at a given level of biological organisation, to be related to 
doses in other assays or at other levels of biological organisation. The dose at the target site 
(influenced in vivo by absorption, distribution, metabolism and excretion parameters and in vitro by 
binding to test system components) is a key determinant of the ultimate biological effect of a chemical 
[1]. The framework for an AOP, in contrast to a source to outcome pathway, is depicted in figure 1. 
 
FIGURE 1 HERE 
 
It is important to define the site of action of the MIE, as this directly determines the nature of the 
adverse outcome and can relate to chronic or acute toxicological effects at the local or systemic level. 
Note that whilst AOPs are usually presented linearly, whereby a graphical representation indicates the 
information blocks in a consecutive way, in reality many other factors may influence the progress from 
MIE to outcome, such as physiological feedback mechanisms and adaptive responses.  
AOPs originate from the field of ecotoxicology, where the approach was proposed to enable the 
formation of toxicologically meaningful categories (TMCs) [4]. Grouping chemicals together into TMCs 
allows for read-across of activity between those chemicals with known activity and chemicals of 
unknown activity. Examples of applying read-across to toxicity of pharmaceuticals are discussed by 
Owen et al [5]. 
Detailed examples of AOPs in the area of ecotoxicology have previously been reported wherein the 
key events are identified and their potential use in regulatory toxicology is discussed. Schultz 
describes three AOPs relating to fish acute toxicity, including weak acid respiratory uncoupling, 
respiratory irritation and acetylcholinesterase inhibition in addition to AOPs for receptor binding of 
oestrogen mimics and skin sensitisation [4]. Ankley et al reported AOPs for narcosis, photoactivated 
toxicity, activation of the aryl hydrocarbon receptor (AhR), oestrogen receptor activation and a set of 
AOPs associated with impaired vitellogenesis (an apposite example of different MIEs resulting in the 
same adverse outcome) [1]. More recently AOPs for human toxicological endpoints have been 
published, including drug-induced liver fibrosis, steatosis [6] and cholestasis [7]. At a global level the 
Organisation for Economic Cooperation and Development (OECD) has recognised the importance of 
the AOP approach, launching its program for the development of AOPs in 2012. At time of writing, 18 
AOPs and 3 case studies are in development with additional ongoing projects relating to 
documentation and knowledge management (http://www.oecd.org/env/ehs/testing/adverse-outcome-
pathways-molecular-screening-and-toxicogenomics.htm#Documents). A guidance document and 
reporting template for the development and assessment of completeness of newly postulated AOPs 
have been published [2]. This document clearly states the criteria by which a proposed AOP should be 
evaluated. Consideration is given to the strength of the scientific data collated and the causal link 
between the steps in the pathway. AOP evaluation is carried out by meeting the Bradford-Hill criteria 
which define the minimal requirements for establishing a causal link between the different information 
blocks [2, 3, 8]. Overall confidence in the AOP is assessed by considering how well the MIE and 
adverse outcome are characterised and if there are any limitations (e.g. related to life-stages of 
organisms). Throughout AOP evaluation, the extent to which the MIE and key events are conserved 
across species is specifically considered. This is relevant in the context of this paper, as it 
demonstrates the utility of the AOP approach in developing predictive models applicable across 
species. 
AOPs have potential use for a variety of purposes pertinent to ecological and human toxicology and 
risk assessment. At the theoretical level they can provide greater understanding of the mechanisms of 
toxicology and enable the establishment of (quantitative) structure-activity relationships. From a 
regulatory perspective improvements in predicting properties of related chemicals, the development of 
novel in vitro toxicity screening tests and the elaboration of prioritisation strategies [3] are also highly 
relevant applications. Such AOP-based approaches can be included in integrated testing strategies 
(ITS) which are considered tools of the future for regulatory risk assessment. The AOP framework 
provides an ideal opportunity for the synergistic use of data from a range of novel in silico and in vitro 
approaches, such as those described below.  
 
Contribution of in silico modelling to adverse outcome pathway development 
In silico (i.e. computational) methods to predict toxicity of chemicals have been widely used in 
environmental sciences for over 40 years. The science is based on the premise that the activity (e.g. 
toxicity) effected by a chemical is a consequence of its physico-chemical and structural properties. 
Hence, knowledge of a chemical’s properties (or knowledge of related chemicals) can be used to 
make predictions on activity. Many (quantitative) structure-activity relationship ((Q)SAR) models have 
been developed for forecasting toxicity to aquatic and terrestrial species, with application to acute 
toxicity to aquatic species being most successful. (Q)SARs work well when the applied dose can be 
clearly linked to the dose at the site of action as occurs for continuous exposure that results in a 
steady-state concentration in the organism. In this case the external dose is proportional to the dose at 
the target site i.e. the dose that causes the effect. Knowledge and expertise in predictive 
eco(toxicology) have been translated into software packages for predicting both acute and chronic 
toxicity in a range of environmental species. Table 1 shows some of the packages currently available. 
 
TABLE 1 HERE 
 
Many in silico tools are available to predict acute toxicity, however, the prediction of adverse effects 
due to repeat, low dose exposure, particularly for complex endpoints such as reproductive toxicity, 
remains a challenging issue. In silico models, in common with other models, provide a simplistic 
representation of a system, hence the complexities of interactions and moderating processes within an 
organism cannot be fully characterised. Whilst there are limitations in the application of in silico 
models to predicting apical toxicity endpoints, these models can be usefully applied within an AOP 
construct. In silico tools can provide predictions relating to key events within an AOP, most notably 
relating to the first step, i.e. determining which chemicals may elicit an MIE. 
Knowledge derived from mechanistic organic chemistry can be used to identify chemical features that 
may lead to an interaction with a biological macromolecule. For example, an electrophilic chemical 
may react with a biological nucleophile forming a covalent bond to proteins or nucleic acids. Figure 2 
shows that the MIE associated with covalent protein binding may result in different effects in different 
species, in casu respiratory irritation in fish and skin sensitisation in humans. Of key importance is that 
such interactions are predictable from chemical knowledge and can be used in the development of 
structural alerts. These alerts may indicate the potential of a chemical to elicit an MIE, such as protein 
binding. However, this may or may not lead to a downstream adverse effect. Alternatively, structural 
alerts may be developed that are directly associated with a given toxicity. Note that care must be 
taken in applying knowledge from structural alerts (i.e. the lack of an alert within a compound does not 
necessarily imply lack of toxicity). Reviews of alerts associated with covalent protein binding [9] and 
covalent DNA binding [10] have been published. Structural alerts associated with MIEs and the ability 
to elicit specific toxicities are continually being developed. Such alerts have been combined into so-
called profilers (e.g. those used within the OECD QSAR Toolbox) which can be used to place 
chemicals into a category of related chemicals for the purpose of read-across (vide supra) [11]. The 
ability to derive justifiable groupings for chemicals and data being available for sufficient group 
members to enable confidence in the prediction are essential requirements for read-across. Data are 
available from a wide range of sources, although assessment of data quality is recommended prior to 
use [12]. 
 
FIGURE 2 HERE 
 
In silico tools are also being applied to the question of interspecies correlation. Where a molecular 
target is associated with an MIE, conservation of this target across species may identify potentially 
susceptible organisms. Gunnarsson et al. predicted orthologs for 1318 human drug targets in 16 
species. Vertebrates (fish and frogs) showed greater conservation of targets than Daphnia or green 
algae [13]. Whilst orthology is not necessarily associated with common function (similarly a functional 
interaction may occur in non-orthologous proteins), it is possible to use this approach to identify 
potential interactions between pharmaceuticals and protein targets (common MIEs or modes of action) 
that may be conserved across diverse species. LaLone et al. demonstrated the application of 
bioinformatics tools to identify where sequence similarity of molecular targets (associated with MIEs) 
could be used to predict species sensitivity to pharmaceuticals (and other chemicals of known mode of 
action) within an AOP context. Case studies using targets for 17α-ethinyl estradiol, permethrin and 
trenbolone acetate were used to compare known toxicity to species susceptibility derived from 
sequence similarity [14]. Spironolactone acts as an antagonist of the androgen receptor in humans. 
This receptor is conserved across vertebrates but not invertebrates. It has been demonstrated that 
exposure to spironolactone reduced fecundity in fish species, but did not affect the reproduction of 
Daphnia [15]. This illustrates the potential of using this approach (i.e. identifying conserved molecular 
targets associated with an MIE in an AOP framework) to identify environmental species that may be 
sensitive to specific pharmaceuticals. This area is expanding rapidly and as more complete genomes 
for more taxa and more well-curated databases become available, the more widely applicable the 
approach will become.  
Walker and McEldowney investigated the use of molecular docking techniques to predict the effects of 
three common pharmaceuticals (diclofenac, ibuprofen and leveonorgestrel) on environmental species. 
Sequence homology searching was performed for cyclooxygenase 2 (COX2) and the progesterone 
receptor, being the target receptor proteins for the drugs. Receptors in fish and frogs, but not daphnia, 
were shown to bind diclofenac in the same way as the human target, potentially leading to inhibition of 
COX2 function in these species. Similarly, levonogestrel was found to bind at the same site in fish and 
frogs as in humans [16]. Reduced fecundity in fish and frogs exposed to levonogestrel would therefore 
be predicted and is in-keeping with the known ecotoxicity profile for this compound.  
Exposure to a chemical is also a key determinant of toxicity. Physiologically-based pharmacokinetic 
(PBPK) models can be used to determine the concentration of a chemical at a target organ (internal 
exposure). In silico tools are routinely applied in the development of these models, for example in 
predicting physico-chemical properties that are associated with uptake and distribution of chemicals. 
Interspecies differences can readily be accounted for in model development (e.g. differences in tissue 
blood flows, organ weights or metabolic capabilities) allowing extrapolation between species.  
The research outlined above indicates in silico tools play a major role in several areas of predictive 
toxicology, namely during determination of  concentrations at target site, upon defining mechanistic 
interaction with biological targets (eliciting MIEs) and in identifying molecular targets that are 
conserved across species. When combined with information obtained by in vitro experimentation, 
these become powerful tools for informing AOPs. 
 
Contribution of in vitro assays to adverse outcome pathway development 
The identification of the different AOP building blocks may be based upon a literature survey or can be 
retrieved from experimental data. Following a given MIE, the establishment of a sequence of key 
events is the next step. As previously discussed any type of information can be fed into an AOP, 
including structural, in chemico, in silico, "omics-based", in vitro and in vivo data [2, 3]. In vitro tests 
are particularly suitable to reinforce the relevance of key events in AOP constructs as well as to 
identify new ones, which in turn may serve as the basis for the characterisation of biomarkers for 
hazard identification. This has been well exemplified in the case of the neurotoxicity induced by 
domoic acid, an algal toxin with adverse effects on humans and wildlife. Domoic acid is a potent 
agonist of kainate receptors, which increases intracellular calcium concentrations triggering 
excitotoxicity and cell death primarily in the hippocampus. This leads to seizures, impairs learning and 
memory and alters behaviour in some species. Altered neuronal calcium concentration is a key 
process in domoic acid toxicity, which is conserved among most species and that can be readily 
evaluated in vitro [17]. Indeed, several protocols exist to assess intracellular calcium concentration, all 
of which mainly use bioluminescent calcium indicators or chemical fluorescent indicators. 
Measurement of calcium concentrations as such can be accomplished with optical techniques, such 
as confocal or 2-photon excitation laser scanning microscopy, as well as with non-optical methods, 
including electrophysiology or calcium-selective electrodes [18].  
Another example where in vitro methods can assist in ecological AOP development includes adverse 
effects mediated by AhR, which is a nuclear receptor that can be activated by 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD) and structurally related planar aromatic chemicals. AhR can be 
found in a variety of vertebrates, including species of mammals, birds, amphibians, bony fishes, 
cartilaginous fish and jawless fish [19]. AhR induces the expression of xenobiotic biotransformation 
enzymes, and causes toxic effects, such as immunotoxicity, reproductive toxicity and cancer [20]. In 
embryonic zebrafish, TCDD is known to evoke cardiac malformation [21], an effect depending on AhR 
activation [22]. Vertebrates are more sensitive to the effects of TCDD and similar chemicals than 
invertebrates [23]. AhR-mediated toxicity can be considered as a key event in many AOPs that can be 
extrapolated across species. Induction of AhR is measurable in vitro using specific gene report 
assays, such as those based upon luciferase activity. It is hereby critical to consider the appropriate 
AhR isoform, as this might differ between species [19]. Furthermore, activation of AhR can be 
evaluated by studying the expression of classical AhR-responsive genes in mammals and fish, 
including cytochrome P450 1A, nicotinamide adenine dinucleotide (phosphate) dehydrogenase, 
aldehyde dehydrogenase 3, uridine diphosphate glucuronosyltransferase and selected glutathione 
transferases [22]. 
An AOP case study that has gained particular attention the last decade includes (eco)toxicity driven by 
the oestrogen receptor, another nuclear receptor that dictates specific gene expression patterns. In 
fact, binding and activation of this receptor by agonists induces a variety of biological responses, such 
as modified reproduction, gonad alterations, changes in levels of sex steroids and the egg yolk 
protein, vitellogenin, as well as secondary sex characteristics [24]. Regarding the latter, a well-
characterised example of endocrine disruption involved feminisation of male fish, reptiles, birds and 
mammals. This is caused by agonists of the oestrogen receptor, including 17β-estradiol and 17α-
ethinylestradiol, present in relatively high concentrations, in discharges from municipal wastewater 
treatment plants [24, 25]. Effects of hormonally active pharmaceuticals are also discussed by Berg et 
al [26]. The potential of chemicals to activate the oestrogen receptor can be pinpointed in vitro directly 
by oestrogen receptor binding assays or indirectly by monitoring oestrogen receptor-dependent gene 
expression, including vitellogenin [1, 25, 27]. A more recently introduced and holistic approach 
includes the use of toxicogenomic approach to characterise a full transcriptional signature of 
endocrine disruption, in casu in fish [28, 29]. Wilson et al. [30] reviewed the application of 
toxicogenomic data (e.g. proteomics, metabolomics, transcriptomics) to providing a better 
understanding of mechanisms of toxicity and the role of these data in risk assessment. Such data can 
be used also to identify biomarkers (e.g. by detecting changes in gene expression that precede a 
particular cellular reaction), to interpret interspecies differences in response and to corroborate 
existing mode-of-action hypotheses. Hence, advances in this technology will aid both definition of key 
events in an AOP and determination whether or not such effects can be extrapolated across species; 
whenever possible taking dose-related exposure effects into consideration. 
In vitro tools can also be used to verify the domain of applicability of structural alerts, identified in 
silico, in addition to providing corroboration of proposed mechanisms. Perkins et al. evaluated data 
from high-throughput in vitro assays in the US Environmental Protection Agency ToxCast Phase I 
project many of which were designed to assess toxicity associated with known MIEs [31]. The authors 
provide examples of where MIEs are conserved across diverse species, such as toxicity arising from 
binding to the gamma-aminobutyric acidA receptor, interaction with hypothalamus-pituitary-gonad axis 
and inhibition of sex steroid synthesis. In certain cases toxicity may be extrapolated. However, in other 
cases, although the MIE is conserved, the apical endpoint may differ between species. Conversely, 
where there is a lack of conservation across, species extrapolation is not possible, as has been 
demonstrated for interactions with the oestrogen receptor, which is well conserved across vertebrates, 
but not invertebrates. Interspecies differences in route and amount of exposure and metabolism 
should also be considered when extrapolating toxicity data across species [31].  
 
Conclusions and perspectives 
Whilst the importance of AOPs has been recognised at the global level by the OECD [2], this area is 
still in its infancy. A criticism of AOPs is their simplicity and thereby their poor reflection of complex 
toxicological processes. In this context, AOPs must be envisaged as flexible tools that should be 
continuously refined by introducing new data. An increasing number of in silico tools are becoming 
available that may support AOP development. These include software to make predictions of apical 
endpoint toxicity in addition to those dedicated to providing more mechanistic understanding of the 
toxicological process, for example development of structural alerts and profilers (such as those used 
within the OECD Toolbox; table 1). Furthermore, investigations into protein sequence similarity and 
molecular docking tools are helping to resolve the issue extrapolation to diverse species. 
Iterative optimisation of AOPs should ideally consider concentration-time profiles giving a more 
quantitative prediction for external and internal exposure. Similarly, the search should not only be 
pursued for new biomarkers to identify hazard, but also for those that allow exposure assessment [3]. 
Another challenge for future AOP development lies in the implementation of epigenetic mechanisms. 
Indeed, several drugs and environmental pollutants, including endocrine disruptors, perform their 
deleterious actions by interfering with chromatin remodelling processes [32]. Although in vitro assays 
are currently available to mechanistically investigate the different determinants of the epigenetic 
machinery, such as DNA methylation and histone modifications, a major point of debate presently 
relates to the design of such in vitro epigenetic studies in terms of timing and exposure in order to 
appropriately mimic the corresponding in vivo situation [33]. Their meaning in relation to identified and 
currently used biomarkers in risk assessment is often unknown. 
In silico and in vitro models represent (parts of) the true, biological system; incorporating results from 
these approaches into an AOP requires confidence in the information that they provide. Results are 
subject to a degree of uncertainty relating to confidence in predictions or reliability / suitability of 
assays. It is also recognised that there are difficulties in extrapolating in vitro results to the in vivo 
situation, for example in converting in vitro doses to realistic in vivo exposure. Current limitations of the 
AOP approach and areas requiring further development have been identified previously [3]. Formal 
validation of methods can be a lengthy and controversial issue and more work is required in 
developing validation standards, however, pragmatic approaches to assessing reliability / suitability of 
models or assays are widely employed. For example, adherence to the OECD principles for the 
validation of (Q)SARs gives greater confidence to predictions obtained using in silico methods [34].  
Effective integration of data from in chemico, in silico, in vitro and in vivo requires bespoke tools for 
recording and presenting data. Effectopedia (http://effectopedia.org/) is one such tool designed to 
address this problem, providing a freely available common space to collate and organise data relevant 
to AOP development. With the rapid evolution of in vitro and in silico methods and their integration to 
support AOPs, it is anticipated that progress in this nascent area will proceed rapidly over the next few 
years.  
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Figure and table captions 
Figure 1. Representation of the key features of a ‘source to outcome’ and ‘adverse outcome pathway’. 
 
Figure 2. Binding of an electrophile to a nucleophilic group of a protein demonstrating that the same 
molecular initiating event can result in different toxicities in different species. 
 
Table 1. Software for predicting environmental effects of chemicals. 
 Table 1 
 
Software URL Notes 
ADMET Predictor http://www.simulations-
plus.com/Products.aspx?pID=13 
Estimates many properties relating to ADME and toxicity 
(including fish and daphnia acute toxicity) enables new 
models to be built from user’s data 
Discovery Studio 
(DS TOPKAT) 
http://accelrys.com Calculates molecular descriptors and generates 
(Q)SARs for several endpoints including daphnia and 
fish toxicity 
ECOSAR http://www.epa.gov/oppt/newchems/t
ools/21ecosar.htm 
Predicts acute and chronic toxicity to algae, daphnia and 
fish using SARs and knowledge of chemical classes 
CATALOGIC http://oasis-
lmc.org/products/software/catalogic.a
spx 
Includes models for predicting environmental fate and 
acute aquatic toxicity 
ChemProp http://www.ufz.de/index.php?en=6738 Chemical properties estimation software comprising a 
suite of modules for physico-chemical and toxicological 
endpoints 
MCASE(MC4PC) http://www.multicase.com/ Uses automated machine learning to identify structural 
alerts associated with a range of toxicity endpoints 
oCHEM https://ochem.eu/home/show.do Screens chemicals against known structural alerts 
associated with different endpoints 
OECD QSAR 
Toolbox 
http://www.oecd.org/env/ehs/risk-
assessment/theoecdqsartoolbox.htm 
Tool for category formation and read-across; uses 
‘profilers’ to enable grouping 
TerraQSAR http://www.terrabase-inc.com/ Modules predict toxicities using knowledge of molecular 
fragments and a neural network approach 
T.E.S.T. http://www.epa.gov/nrmrl/std/qsar/qsa
r.html#TEST 
Uses seven different methods to predict acute toxicity in 
daphnia and fish (and other endpoints) 
ToxPredict http://apps.ideaconsult.net:8080/ToxP Suite of programs capable of predicting over 50 
redict (eco)toxicological endpoints and properties 
VEGA http://www.vega-qsar.eu/about-
qsar.html 
Provides access to a series of QSAR models for 
predicting a range of toxicities (including daphnia acute 
toxicity) 
WEBICE http://epa.gov/ceampubl/fchain/webic
e/ 
Estimates acute toxicity to fish, invertebrates, birds and 
mammals using knowledge from surrogate species 
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